Josef Scheidt

Mr. Josef Scheidt

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2019 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
AVAmita M Vaidya
Amita M Vaidya
ZSZhanhu Sun
Zhanhu Sun
NANadia Ayat
Nadia Ayat
ASAndrew Schilb
Andrew Schilb
XLXujie Liu
Xujie Liu
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu

1 August 2019 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
NANadia R. Ayat
Nadia R. Ayat
ZSZhanhu Sun
Zhanhu Sun
DSDa Sun
Da Sun
MYMichelle Yin
Michelle Yin
RHRyan C. Hall
Ryan C. Hall
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu
Nanoparticle based siRNA formulations often suffer from aggregation and loss of function during storage. We in this study report a frozen targeted RGD-polyethylene glycol (PEG)-ECO/siβ3 nanoparticle formulation with a prolonged shelf life and preserved nanoparticle functionality. The targeted RGD-PEG-ECO/siβ3 nanoparticles are formed by step-wised self-assembly of RGD-PEG-maleimide, ECO, and siRNA. The nanoparticles have a diameter of 224.5 ± 9.41 nm and a zeta potential to 45.96 ± 3.67 mV in water and a size of 234.34 ± 3.01 nm and a near neutral zeta potential in saline solution. The addition of sucrose does not affect their size and zeta potential and substantially preserves the integrity and biological activities of frozen and lyophilized formulations of the targeted nanoparticles. The frozen formulation with as low as 5% sucrose retains nanoparticle integrity (90% siRNA encapsulation), size distribution (polydispersity index [PDI] ≤20%), and functionality (at least 75% silencing efficiency) at −80°C for at least 1 year. The frozen RGD-PEG-ECO/siβ3 nanoparticle formulation exhibits excellent biocompatibility, with no adverse effects on hemocompatibility and minimal immunogenicity. As RNAi holds the promise in treating the previously untreatable diseases, the frozen nanoparticle formulation with the low sucrose concentration has the potential to be a delivery platform for clinical translation of RNAi therapeutics.

2 October 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAndrew L. Schilb
Andrew L. Schilb
JSJosef Scheidt
Josef Scheidt
AVAmita Vaidya
Amita Vaidya
ZSZhanhu Sun
Zhanhu Sun
DSDa Sun
Da Sun
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu
Nucleic acids are promising for a variety of therapies, such as cancer therapy and the gene therapy of genetic disorders. The therapeutic efficacy of nucleic acids is reliant on the ability of their efficient delivery to the cytosol of the target cells. Amino lipids have been developed to aid in the cytosolic delivery of nucleic acids. This work reports a new and efficient synthetic pathway for the lipid carrier, (1-aminoethyl) iminobis [N-(oleicylcysteinyl-1-amino-ethyl)propionamide] (ECO). The previous synthesis of the ECO was inefficient and presented poor product quality control. A solution-phase synthesis of the ECO was explored, and each intermediate product was characterized with better quality control. The ECO was synthesized with a relatively high yield and high purity. The formulations of the ECO nanoparticles were made with siRNA, miRNA, or plasmid DNA, and characterized. The transfection efficiency of the nanoparticles was evaluated in vitro over a range of N/P ratios. The nanoparticles were consistent in size with previous formulations and had primarily a positive zeta potential. The ECO/siLuc nanoparticles resulted in potent luciferase silencing with minimal cytotoxicity. The ECO/miR-200c nanoparticles mediated the efficient delivery of miR-200c into the target cells. The ECO/pCMV-GFP nanoparticles resulted in substantial GFP expression upon transfection. These results demonstrate that the solution-phase synthetic pathway produced pure ECO for the efficient intracellular delivery of nucleic acids without size limitation.

22 November 2019 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
JSJosef Scheidt
Josef Scheidt
Carbon nanomaterials receive much attention due to enhanced mechanical and electrical properties that arise from nanoconfinement. Carbon nanotubes (CNTs) (3-dimensional) and graphene sheets (2-dimensional) have seen applications as sensors, high-strength fiber reinforcements, and adhesives. Carbyne, a 1-dimensional purely carbon structure consisting of alternating single and triple bonds, is projected to be the strongest material in the known world, with specific strength several times that of CNTs and graphene. Despite its desirable properties, carbyne’s extreme instability under standard conditions has inhibited its commercial development. Recent advancements in carbyne synthesis using CNTs as molecular scaffolds show that carbyne may finally be able to progress from theory to reality. Here, an approach for the preparation and stabilization of long-chain carbyne without the use of CNTs is proposed. Using multilevel pulse-voltage injection (MLPI) to create uniform, subnanometer diameter pores in silicon nitride as thermally stable nanoreactors, initial theoretical calculations suggest that carbyne may be synthesized under high temperature and vacuum. Carbyne chains may then be extracted from the pores and subsequently stabilized by immersion into a solution of poly(diallyldimethylammonium chloride) (PDDA). The long-chain carbyne is then free to be used for a multiplicity of applications, including low-threshold sensors and the realization of high-strength carbyne fibers.

22 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAndrew L. Schilb
Andrew L. Schilb
JSJosef Scheidt
Josef Scheidt
AVAmita Vaidya
Amita Vaidya
ZSZhanhu Sun
Zhanhu Sun
DSDa Sun
Da Sun
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu
There was an error in the original publication